

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Confirmation No. 1789
Frederic J. de SAUVAGE, et al.)	Examiner: HAYES, Robert Clinton
Application Serial No. 10/621,855)	Art Unit: 1653
Filed: July 16, 2003)	Attorney's Docket No. 39766-0065 DV1
For: GFRα3 AND ITS USES)	Customer No. 25213
)	

EXPRESS MAIL LABEL NO. EV 765 988 891 US
DATE MAILED: December 13, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450


Sir:

Applicants wish to bring to the attention of the Patent Office the references listed on the attached Form PTO-1449 and request that the listed information be considered by the Examiner and be made of record in the above-identified application. Each of the references listed on the attached Form PTO-1449 was previously cited by or submitted to the PTO in prior Application Serial No. 09/272,835. Since all references were previously cited by or submitted to the PTO, no references are enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b)(3), therefore no fee is due. The Commissioner is hereby authorized to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641**, referencing Attorney's Docket No. **39766-0065 DV1**.

Respectfully submitted,

Dated: December 13, 2005

By: 
James A. Fox (Reg. No. 38,455)

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

SV 2172721 v1

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i>		Attorney's Docket No. 39750-0065DV1		Application Serial No. 10/621,855			
		Applicant(s) Frederic J. de SAUVAGE, et al.					
		Filing Date: July 16, 2003		Group Art Unit: 1653			
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class s	Subclass ss	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class s	Subclass ss	Translation YES NO
OTHER DOCUMENTS <i>(including author, title, date, pertinent pages, etc.)</i>							
Examiner Initials	Ref. No.	Title					
	1	Andres et al., <i>Development</i> 128(10):3685-3695 (2001) Multiple effects of artemin on sympathetic neurone generation, survival and growth					
	2	Baloh et al., <i>Neuron</i> 21: 1291-1302 (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex					
	3	Esteva, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," <i>The Oncologist</i> 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).					
	4	Negro et al., <i>Recent Prog Horm Res.</i> 59:1-12 (2004) Essential roles of Her2/erbB2 in cardiac development and function					
	5	Rosická et al., <i>Physiological Research</i> 51:435-441 (2002) Ghrelin - a New Endogenous Growth Hormone Secretagogue/					
	6	Smith et al., <i>Best Pract Res Clin endocrinol Metab.</i> 18(3):333-347 (2004) Growth hormone secretagogues: prospects and potential pitfalls					
	7	Thilenius et al., <i>Eur. J. Immunol.</i> 27(5):1108-1114 (1997) Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants					
EXAMINER:				DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).							